Şunu aradınız:: stamcelletransplantation (Danca - İngilizce)

hæmatopoietisk stamcelletransplantation
haematopoietic stem cell transplant

patienter, som er egnede til stamcelletransplantation
patients eligible for stem cell transplantation

hypogammaglobulinæmi hos patienter efter allogen hæmatopoietisk stamcelletransplantation
hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation

hypogammaglobulinæmi hos patienter før eller efter allogen hæmatopoietisk stamcelletransplantation.
hypogammaglobulinaemia in patients pre- and post-allogeneic hematopoietic stem cell transplantation (hsct).

efter behandlingen med evoltra kunne 10 patienter gennemgå en stamcelletransplantation.
after treatment with evoltra, 10 patients were able to go on to have a stem cell transplant.

80 % af patienterne havde tidligere fået autolog stamcelletransplantation (asct).
eighty percent of patients had received prior autologous stem cell transplantation (asct).

hvis du har fået en stamcelletransplantation (en slags knoglemarvstransplantation) fra en donor.
if you have received a stem cell transplant (a kind of bone marrow transplant) from a donor.

efter behandlingen med evoltra kunne 10 patienter gå videre til at få en stamcelletransplantation.
after treatment with evoltra, 10 patients were able to go on to have a stem cell transplant.

accofil og perifer blod stamcelletransplantation (stamceller opsamlet fra blodet til brug ved knoglemarvstransplantation)
accofil and peripheral blood stem cell transplantation (stem cells collected from the blood to use in bone marrow transplantation)

størstedelen af patienterne havde fået rituximab i kombination med kemoterapi eller som en del af en hæmatopoietisk stamcelletransplantation.
the majority of patients had received rituximab in combination with chemotherapy or as part of a hematopoetic stem cell transplant.

mobilisering af pbpc giver ikke nogen direkte klinisk fordel for raske donorer og skal kun anvendes ved allogen stamcelletransplantation.
mobilisation of pbpc does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.

dosering til patienter med tidligere ubehandlet myelomatose, som er egnede til hæmatopoietisk stamcelletransplantation (induktionsbehandling)
posology for previously untreated multiple myeloma patients eligible for haematopoietic stem cell transplantation (induction therapy)

mobilisering af perifere blodstamceller giver ikke nogen direkte klinisk fordel for raske donorer og bør kun anvendes ved allogen stamcelletransplantation.
mobilisation of pbpc does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.

patienter i enkeltcenterstudiet havde relaps efter 1-6 forudgående terapiregimer, og 2 patienter havde relaps efter stamcelletransplantation.
patients in the single centre study had relapsed following 1-6 prior therapy regimens and 2 patients had relapsed following stem cell transplantation.

den anden undersøgelse omfattede 488 aml-patienter, som var mindst 65 år, og som ikke kunne gennemgå en hæmatopoietisk stamcelletransplantation.
the second study involved 488 patients with aml who were 65 years or older and could not have haematopoietic stem cell transplantation.

stamcelletransplantation eller patienter, der forventes at få neutropeni (absolut neutrofiltal 500 celler/µl) i 10 dage eller mere.
transplantation or patients who are expected to have neutropenia (absolute neutrophil count 500 cells/µl) for 10 or more days.

raske donorer før allogen perifer blodstamcelle- transplantation mobilisering af perifere blodstamceller giver ikke nogen direkte klinisk fordel for raske donorer og bør kun anvendes ved allogen stamcelletransplantation.
normal donors prior to allogeneic pbpc transplantation mobilisation of pbpc does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.

105 (81 %) og 78 (61 %) patienter i henholdsvis bztdx og tdx-gruppen fik en enkelt autolog stamcelletransplantation.
one single autologous stem cell transplant was received by 105 (81%) patients and 78 (61%) patients in the bztdx and tdx groups, respectively.

9 4 forskellige induktionsregimer, og 18/ 61 (30%) af disse patienter havde fået mindst 1 tidligere hæmatologisk stamcelletransplantation (hsct).
before enrolling in the trial, 58 of the 61 patients (95%) had received 2 to 4 different induction regimens and 18/ 61 (30%) of these patients had undergone at least 1 prior haematological stem cell transplant (hsct).

patienter, især børn med risikofaktorer for akut pancreatitis (f. eks. nylig kemoterapi, hæmatopoietisk stamcelletransplantation (hsct)) bør monitoreres tæt under vfend- behandling.
patients, especially children, with risk factors for acute pancreatitis (e. g. recent chemotherapy, hematopoietic stem cell translplantation (hsct)), should be monitored closely during vfend treatment.